Clinical trials: Drug Eluting Stents
Coronary Artery Disease (CAD)
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
To determine the efficacy of prasugrel versus clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting…
- Trial name
- TRIGGER-PCI (NCT00910299)
- Testing
- Prasugrel, Clopidogrel
- Where
- 27 sites in United States, Germany
- Volunteers
- 423 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
e-BioMatrix PostMarket Surveillance Registry
The purpose of the e-BioMatrix PMS registry is to capture clinical data of the BioMatrix (Biolimus A9-Eluting) stent system in relation to safety and effectiveness.
- Trial name
- NCT01254487
- Where
- 9 sites in Spain, Switzerland and 1 more
- Volunteers
- 1,121 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease
JACTAX LD Drug Eluting Stent Trial
Prospective, multi-center, randomized trial. A maximum of 130 patients will be enrolled, in a 2:1 ratio to receive either the JACTAX LD stent or the TAXUS™ Libertè™ stent to evaluate the efficacy of the product.
- Trial name
- NCT00754975
- Testing
- JACTAX LD DES, TAXUS™ Libertè™ DES
- Where
- 5 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Boston Scientific Corporation
Coronary Heart Disease
TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)
The goal of the TAXUS™ Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study is to evaluate real world clinical outcomes data for the TAXUS™ Element™ Coronary Stent System in unselected…
- Trial name
- TE-Prove (NCT01242696)
- Testing
- Coronary artery stenting
- Where
- 37 sites in Belgium, France and 8 more
- Volunteers
- 1,014 people
- Sponsor
- Boston Scientific Corporation
Stable Coronary Disease, Unstable Coronary Disease
Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen
To evaluate the safety and efficacy of the Janus OPTIMA Tacrolimus-Eluting Stent (Optima TES, CID) for the treatment of de novo coronary lesions when associated with short-term (two months) dual antiplatelet (aspirin +…
- Conditions
- Stable Coronary Disease, Unstable Coronary Disease, Documented Silent Ischemia
- Trial name
- BEST (NCT01122719)
- Testing
- Drug Eluting Stent
- Where
- 2 sites in Brazil, Italy
- Volunteers
- 16 people
- Sponsor
- CID - Carbostent & Implantable Devices
Coronary Artery Disease, Drug-coated Balloon
Long-term Efficacy of Drug-coated Balloon Versus Drug-eluting Stent in Large de Novo Coronary Lesions
To evaluate the efficacy of drug-coated balloon versus drug-eluting stent for the treatment of large de novo coronary lesions(RVD=2.75~4.0mm).
- Trial name
- NCT05101005
- Testing
- Drug-Coated Balloon, Sirolimus-Eluting Stent
- Volunteers
- 400 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Drug-eluting Stent
Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention
Clinical trial with an "European Community marked" medical device in patients with ischemic heart disease and clinical indication of coronary revascularization with drug-eluting stent.
- Trial name
- NCT03049657
- Testing
- Angiolite, Xience
- Where
- 11 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Cardiva2 S.L.
Coronary Artery Disease
Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE
Prospective, multicenter, single arm registry to monitor post-market clinical outcomes of patients treated with Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer.
- Trial name
- LATITUDE (NCT03471234)
- Testing
- Angioplasty
- Where
- 2 sites in Brazil
- Volunteers
- 299 people
- Sponsor
- Scitech Produtos Medicos SA
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Observational Prospective Study OPTIMA II - Follow-up
The current follow-up study was planned to reveal the rates of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) during 4-year follow-up in patients participated in OPTIMA study.
- Trial name
- OPTIMAII (NCT02099565)
- Where
- Russia
- Volunteers
- 572 people
- Sponsor
- AstraZeneca
Critical Limb Ischemia
The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs.
- Trial name
- SAVAL (NCT03551496)
- Testing
- Drug Eluting Stent - Below the Knee, Standard PTA Control Arm
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
The ultimate goal of a paclitaxel eluting stent system (TAXUS stent) is to prevent restenosis by blunting the initial response to stent implant injury and sustaining the arrested response until vascular healing has taken place.
- Trial name
- NCT00292474
- Testing
- percutaneous coronary intervention
- Where
- United States
- Volunteers
- 1,326 people
- Sponsor
- Boston Scientific Corporation
AMI
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent
The trial aims to evaluate 12-month long-term efficiency of Excel stent in the treatment of coronary heart disease and inhibition of restenosis after coronary artery stenting as well as a 12 months' long-term safety after the…
- Trial name
- CREATE (NCT00331578)
- Testing
- Excel drug-eluting coronary artery stent
- Volunteers
- 2,077 people
- Sponsor
- JW Medical Systems Ltd
Atherosclerosis, Heart Diseases, Coronary
A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)
EVOLVE 4.5/5.0 is a prospective, single-arm, multi-center observational (standard of care) trial intended to confirm the safety and effectiveness of the SYNERGY 4.50 mm and 5.00 mm Coronary Stent System for the treatment of…
- Conditions
- Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03875651
- Testing
- SYNERGY 4.50 mm and 5.0 mm Coronary Stent System
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Atherosclerosis, Heart Diseases, Coronary
A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System
This is a post-market, standard of care, real-world observational study to assess the clinical outcomes of the SYNERGY XLV (MEGATRON) Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 28 mm in…
- Conditions
- Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT04807439
- Testing
- SYNERGY XLV (Megatron) Coronary Stent System
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions
The purpose of the this trial is to evaluate the clinical safety and efficacy of Cilostazol eluting stent system (CES-1) for the treatment of single de novo lesions in native coronary arteries.
- Trial name
- NCT03189641
- Testing
- Cilostazol eluting stent system (CES-1)
- Where
- 6 sites in Japan
- Volunteers
- 30 people
- Sponsor
- JIMRO Co., Ltd.
Coronary Disease
Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety
This trial aims to demonstrate the non-inferiority of the CI-CMS-005 Coronary Stent System to the study device as well as to the TAXUS™ Express2™ Drug-Eluting Coronary Stent System in in-segment late lumen loss at 9 months after…
- Trial name
- NCT00415961
- Testing
- CoStar Paclitaxel Drug-Eluting Coronary Stent System
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Conor Medsystems
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Atherosclerosis
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
OBJECTIVE It is the objective of the REMEDEE OCT study to assess vascular healing after deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) in patients with Acute…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Acute Coronary Syndrome (ACS), Myocardial Infarction (MI)
- Trial name
- REMEDEE-OCT (NCT01405287)
- Testing
- PTCA with stent placement
- Where
- 6 sites in Belgium, Finland and 3 more
- Volunteers
- 60 people
- Sponsor
- OrbusNeich
Arterial Occlusive Diseases, Myocardial Ischemia
RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent
The objective of the study is to verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent for the treatment of de novo lesions in native coronary arteries.
- Conditions
- Arterial Occlusive Diseases, Myocardial Ischemia, Cardiovascular Diseases, Coronary Artery Disease
- Trial name
- RJ (NCT00927940)
- Testing
- MDT-4107 Drug Eluting Stent
- Where
- 14 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Medtronic Vascular
Coronary Heart Disease
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study
The goal of the PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study is to evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected…
- Trial name
- PE-Prove (NCT01148329)
- Testing
- Coronary stenting
- Where
- 40 sites in Austria, Belgium and 9 more
- Volunteers
- 1,010 people
- Sponsor
- Boston Scientific Corporation